Zentera Raises $75 Million to Develop Three Cancer Candidates in China
August 02, 2021 at 06:23 AM EDT
Shanghai Zentera Therapeutics raised $75 million in a Series B financing to support clinical development of its three main cancer drug candidates. In 2020, Zentera was formed by Zentalis Pharma of New York City as a JV for China development of its assets, which target cancer biological pathways. Zentera will use the proceeds for clinical development and to add new candidates to its portfolio. Founding investors OrbiMed Advisors Asia and Tybourne Capital Management led the B round. More details.... Stock Symbol: (NSDQ: ZNTL) Share this with colleagues: // //
